Elacestrant Outperforms SOC in Terms of PFS in ER+/HER2– mBC
Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.
T-DXd Improves Survival in HER2-Positive BC Versus Capecitabine-Based Regimens
Patients with advanced HER2-positive breast cancer had better progression-free and overall survival outcomes when given trastuzumab deruxtecan versus capecitabin-based treatment.